Cargando…

Substance-induced anxiety disorder after one dose of 3,4-methylenedioxymethamphetamine: a case report

BACKGROUND: In this report, we describe a case of a patient with substance-induced anxiety disorder occurring after a single dose of 3,4-methylenedioxymethamphetamine. Furthermore, we describe the use and efficacy of the Primary Care Behavioral Health model, a collaborative approach to integrative p...

Descripción completa

Detalles Bibliográficos
Autores principales: Kaplan, Kaeley, Kurtz, Fiona, Serafini, Kelly
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5968564/
https://www.ncbi.nlm.nih.gov/pubmed/29793521
http://dx.doi.org/10.1186/s13256-018-1670-7
_version_ 1783325794735489024
author Kaplan, Kaeley
Kurtz, Fiona
Serafini, Kelly
author_facet Kaplan, Kaeley
Kurtz, Fiona
Serafini, Kelly
author_sort Kaplan, Kaeley
collection PubMed
description BACKGROUND: In this report, we describe a case of a patient with substance-induced anxiety disorder occurring after a single dose of 3,4-methylenedioxymethamphetamine. Furthermore, we describe the use and efficacy of the Primary Care Behavioral Health model, a collaborative approach to integrative primary mental health care, in evaluating and treating this rare mental health disorder. CASE PRESENTATION: Three days following ingestion of one dose of 3,4-methylenedioxymethamphetamine, a 35-year-old Hispanic man with no significant prior mental health history and no history of prior 3,4-methylenedioxymethamphetamine use presented to our hospital with severe, acute anxiety and panic symptoms. He was initially treated with a combination of behavioral therapy and the serotonin agonist buspirone. Buspirone ultimately proved ineffective, so it was discontinued in favor of the selective serotonin reuptake inhibitor sertraline. While awaiting the pharmacological onset of sertraline, the patient worked with a behavioral health consultant, who provided psychoeducation on the experience of panic, building relaxation skills, and modifying maladaptive thought patterns. Enhanced communication between the primary care provider and behavioral health consultant facilitated the planning and enactment of the patient’s care plan. Approximately 2.5 months after his initial ingestion of 3,4-methylenedioxymethamphetamine, the patient’s symptoms subsided. This improvement was attributed to the combination of the behavioral health intervention and sertraline at a dose of 50 mg daily. Six months after 3,4-methylenedioxymethamphetamine ingestion, the patient began to gradually taper sertraline and has had no resurgence of anxiety symptoms to date. CONCLUSIONS: Our patient’s case not only demonstrates a rare presentation of 3,4-methylenedioxymethamphetamine-induced anxiety disorder but also provides support for the use of the Primary Care Behavioral Health model to deliver individualized, timely mental health care in a primary care setting.
format Online
Article
Text
id pubmed-5968564
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-59685642018-05-30 Substance-induced anxiety disorder after one dose of 3,4-methylenedioxymethamphetamine: a case report Kaplan, Kaeley Kurtz, Fiona Serafini, Kelly J Med Case Rep Case Report BACKGROUND: In this report, we describe a case of a patient with substance-induced anxiety disorder occurring after a single dose of 3,4-methylenedioxymethamphetamine. Furthermore, we describe the use and efficacy of the Primary Care Behavioral Health model, a collaborative approach to integrative primary mental health care, in evaluating and treating this rare mental health disorder. CASE PRESENTATION: Three days following ingestion of one dose of 3,4-methylenedioxymethamphetamine, a 35-year-old Hispanic man with no significant prior mental health history and no history of prior 3,4-methylenedioxymethamphetamine use presented to our hospital with severe, acute anxiety and panic symptoms. He was initially treated with a combination of behavioral therapy and the serotonin agonist buspirone. Buspirone ultimately proved ineffective, so it was discontinued in favor of the selective serotonin reuptake inhibitor sertraline. While awaiting the pharmacological onset of sertraline, the patient worked with a behavioral health consultant, who provided psychoeducation on the experience of panic, building relaxation skills, and modifying maladaptive thought patterns. Enhanced communication between the primary care provider and behavioral health consultant facilitated the planning and enactment of the patient’s care plan. Approximately 2.5 months after his initial ingestion of 3,4-methylenedioxymethamphetamine, the patient’s symptoms subsided. This improvement was attributed to the combination of the behavioral health intervention and sertraline at a dose of 50 mg daily. Six months after 3,4-methylenedioxymethamphetamine ingestion, the patient began to gradually taper sertraline and has had no resurgence of anxiety symptoms to date. CONCLUSIONS: Our patient’s case not only demonstrates a rare presentation of 3,4-methylenedioxymethamphetamine-induced anxiety disorder but also provides support for the use of the Primary Care Behavioral Health model to deliver individualized, timely mental health care in a primary care setting. BioMed Central 2018-05-25 /pmc/articles/PMC5968564/ /pubmed/29793521 http://dx.doi.org/10.1186/s13256-018-1670-7 Text en © The Author(s). 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Case Report
Kaplan, Kaeley
Kurtz, Fiona
Serafini, Kelly
Substance-induced anxiety disorder after one dose of 3,4-methylenedioxymethamphetamine: a case report
title Substance-induced anxiety disorder after one dose of 3,4-methylenedioxymethamphetamine: a case report
title_full Substance-induced anxiety disorder after one dose of 3,4-methylenedioxymethamphetamine: a case report
title_fullStr Substance-induced anxiety disorder after one dose of 3,4-methylenedioxymethamphetamine: a case report
title_full_unstemmed Substance-induced anxiety disorder after one dose of 3,4-methylenedioxymethamphetamine: a case report
title_short Substance-induced anxiety disorder after one dose of 3,4-methylenedioxymethamphetamine: a case report
title_sort substance-induced anxiety disorder after one dose of 3,4-methylenedioxymethamphetamine: a case report
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5968564/
https://www.ncbi.nlm.nih.gov/pubmed/29793521
http://dx.doi.org/10.1186/s13256-018-1670-7
work_keys_str_mv AT kaplankaeley substanceinducedanxietydisorderafteronedoseof34methylenedioxymethamphetamineacasereport
AT kurtzfiona substanceinducedanxietydisorderafteronedoseof34methylenedioxymethamphetamineacasereport
AT serafinikelly substanceinducedanxietydisorderafteronedoseof34methylenedioxymethamphetamineacasereport